M06.259 Rheumatoid bursitis, unspecified hip

Name of the Condition

• Rheumatoid bursitis, unspecified hip

Summary

Rheumatoid bursitis of the unspecified hip is inflammation of the bursae (fluid-filled sacs that cushion joints) in the hip region, driven by rheumatoid arthritis (RA). This condition results from the immune system’s chronic inflammatory processes affecting the hip’s protective structures, leading to pain, swelling, and restricted mobility. Diagnosis requires correlation of clinical findings with RA history or serologic evidence.

Causes

Rheumatoid bursitis in the unspecified hip arises from the systemic inflammation of rheumatoid arthritis. The immune system’s attack on joint tissues extends to the hip’s bursae, causing fluid accumulation and irritation. While RA is the primary driver, mechanical stress or trauma to the hip may exacerbate inflammation in susceptible individuals.

Risk Factors

• Preexisting rheumatoid arthritis, increasing bursal inflammation risk.
• Advanced age, as RA severity often progresses over time.
• Prolonged hip overuse or pressure, which may irritate bursae.
• Systemic inflammation, as seen in active RA flares.

Symptoms

• Localized swelling and tenderness over the hip bursae.
• Pain with hip movement or pressure on the inflamed area.
• Reduced range of motion in the hip joint.
• Warmth or redness (if inflammation is acute).

Diagnosis

Diagnosis of rheumatoid bursitis, unspecified hip, involves correlating clinical findings with a history of rheumatoid arthritis or serologic evidence of RA. Physical examination may reveal tenderness, swelling, or limited hip mobility. Imaging (e.g., ultrasound or MRI) can assess bursal inflammation, while laboratory tests (e.g., rheumatoid factor, anti-CCP antibodies) support the underlying RA diagnosis. Exclusion of other causes (e.g., septic bursitis, gout) is essential.

Treatment Options

Treatment focuses on reducing inflammation and managing RA. Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroid injections may alleviate pain and swelling. Disease-modifying antirheumatic drugs (DMARDs) or biologics target systemic RA activity. Physical therapy improves hip mobility and strength. In severe cases, surgical intervention (e.g., bursectomy) may be considered.

Prognosis and Follow-Up

Prognosis depends on RA control and adherence to treatment. With proper management, symptoms often improve, but chronic inflammation may lead to persistent discomfort or functional limitations. Regular follow-up with a rheumatologist or orthopedist monitors disease activity and adjusts therapy. Flare-ups require prompt intervention to prevent complications.

Complications

Untreated or poorly controlled inflammation may cause chronic pain, reduced mobility, or bursal thickening. Rarely, infection or tissue damage can occur. Systemic RA progression may exacerbate hip involvement, increasing disability risk.

Lifestyle & Prevention

Maintain RA control through prescribed medications and regular exercise to preserve hip function. Avoid prolonged pressure or repetitive hip movements that irritate bursae. Weight management reduces hip stress. Early RA treatment minimizes bursal inflammation risk.

When to Seek Professional Help

Seek care if hip pain, swelling, or stiffness persists despite home care, or if symptoms worsen. Immediate attention is needed for sudden severe pain, fever, or signs of infection (e.g., redness, warmth), which may indicate septic bursitis.

Tips for Medical Coders

Use M06.259 for rheumatoid bursitis of the unspecified hip. Document the hip’s involvement (unspecified) and confirm RA as the underlying cause. Ensure clinical correlation with RA history or serologic evidence to support the diagnosis. Avoid using this code for non-RA-related bursitis or specified hip involvement (e.g., right/left).